It also inhibits tumorigenesis in prostate cancer via reducing FGF-2-mediated angiogenesis; it negatively regulates angiogenesis by proteolytically inactivating fibroblast growth factor-2 [55, 56]. This evidence concerns the gene FGF2 and prostate cancer.